Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
6.47
-0.02 (-0.31%)
May 2, 2025, 4:00 PM EDT - Market closed
Kura Oncology Revenue
Kura Oncology had revenue of $14.11M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $67.99M. In the year 2024, Kura Oncology had annual revenue of $53.88M.
Revenue (ttm)
$67.99M
Revenue Growth
n/a
P/S Ratio
8.28
Revenue / Employee
$354,120
Employees
192
Market Cap
560.14M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
KURA News
- 17 hours ago - Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 1 day ago - Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Kura Oncology Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 4 days ago - Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST - GlobeNewsWire
- 8 days ago - Kura Oncology to Report First Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA - GlobeNewsWire
- 4 weeks ago - Kura Oncology to Participate in Stifel Targeted Oncology Forum - GlobeNewsWire
- 5 weeks ago - Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting - GlobeNewsWire